Skip to main content

Advertisement

SpringerLink
Log in

Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Our aim is to evaluate whether previous non-urothelial malignant history affects the clinical outcomes of patients with non-muscle invasive bladder cancer (NMIBC).

Patients and Methods

We identified 1097 cases treated by transurethral resection of bladder tumors for initially diagnosed NMIBC at our four institutions between 1999 and 2017. We compared clinical characteristics and outcomes between NMIBC patients with and without previous non-urothelial malignant history and investigated whether smoking status and treatment modality for previous cancer affected NMIBC outcomes.

Results

A total of 177 patients (16.1%) had previous non-urothelial malignant history (malignant history group). The 5-year recurrence-free survival rate and the 5-year progression-free survival rate in the malignant history group was 46.4% and 88.3%, respectively, which was significantly lower than that in the counterpart (60.2% p = 0.004, and 94.5% p = 0.002, respectively). A multivariate Cox regression analysis identified previous non-urothelial malignant history as an independent risk factor for tumor recurrence (p = 0.001) and stage progression (p = 0.003). In a subgroup of patients who were current smokers (N = 347), previous non-urothelial malignant history was associated with tumor recurrence and stage progression. In contrast, previous non-urothelial malignant history was not associated with tumor recurrence or stage progression in ex-smokers or non-smokers. In a subgroup analysis of NMIBC patients with previous prostate cancer history, those treated with androgen deprivation therapy had a significantly lower bladder tumor recurrence rate than their counterparts (p = 0.027).

Conclusions

Previous history of non-urothelial malignancy may lead to worse clinical outcome in patients with NMIBC, particularly current smokers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Phys. 2017;96:507–14.

    Google Scholar 

  2. Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388:2796–810.

    Article  Google Scholar 

  3. Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3:1554–7.

    Article  Google Scholar 

  4. Deng L, Harðardottír H, Song H, et al. Mortality of lung cancer as a second primary malignancy: a population-based cohort study. Cancer Med. 2019;8:3269–77.

    Article  Google Scholar 

  5. Anderson JK, Alanee S, Lindgren B, Slaton J. The risk of bladder cancer in patients diagnosed with other primary neoplasms: analysis of the SEER database. Urol Oncol. 2013;31:862–5.

    Article  Google Scholar 

  6. Bermejo JL, Sundquist J, Hemminki K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer. 2009;101:1091–9.

    Article  Google Scholar 

  7. Aljabery F, Liedberg F, Häggström C, et al. Treatment and prognosis of bladder cancer patients with other primary cancers. A nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe). BJU Int. 2020;126(5):625–32. https://doi.org/10.1111/bju.15198.

    Article  PubMed  Google Scholar 

  8. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734–45.

    Article  Google Scholar 

  9. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003;105:484–90.

    Article  CAS  Google Scholar 

  10. Sanguedolce F, Cormio A, Massenio P, et al. Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol. 2018;144:637–44.

    Article  CAS  Google Scholar 

  11. Varol U, Kucukzeybek Y, Alacacioglu A, et al. BRCA genes: BRCA 1 and BRCA 2. J BUON. 2018;23:862–6.

    PubMed  Google Scholar 

  12. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79–86.

    Article  Google Scholar 

  13. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:4975–83. https://doi.org/10.1097/MD.0000000000004975.

    Article  CAS  Google Scholar 

  14. Weinstein J, Akbani R, Broom B, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.

    Article  CAS  Google Scholar 

  15. Stracci F, D’Alò D, Cassetti T, Scheibel M, Rosa FL. Incidence of multiple primary malignancies in women diagnosed with breast cancer. Eur J Gynaecol Oncol. 2009;30:661–3.

    CAS  PubMed  Google Scholar 

  16. Meeks JJ, Carneiro BA, Pai SG, et al. Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget. 2016;7:75176–84.

    Article  Google Scholar 

  17. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol. 1995;142:653–65.

    Article  CAS  Google Scholar 

  18. Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. Ann Oncol. 2013;24:2699–704.

    Article  CAS  Google Scholar 

  19. Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem. 2004;279:23837–44.

    Article  CAS  Google Scholar 

  20. Nishioka T, Kim HS, Luo LY, Huang Y, Guo J, Chen CY. Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth. Breast Cancer Res. 2011;13:113–23. https://doi.org/10.1186/bcr3055.

    Article  CAS  Google Scholar 

  21. Xu J, Huang H, Pan C, Zhang B, Liu X, Zhang L. Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. Int J Oral Maxillofac Surg. 2007;36:739–44.

    Article  CAS  Google Scholar 

  22. Yuge K, Kikuchi E, Hagiwara M, et al. Nicotine induces tumor growth and chemoresistance through activation of the PI3K/Akt/mTOR pathway in bladder cancer. Mol Cancer Ther. 2015;14:2112–20.

    Article  CAS  Google Scholar 

  23. Fahmy M, Mansure JJ, Brimo F, et al. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol. 2013;44:1766–72.

    Article  CAS  Google Scholar 

  24. Izumi K, Taguri M, Miyamoto H, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014;5:12665–74.

    Article  Google Scholar 

  25. Kim A, Kim MS, Ahn JH, et al. Clinical significance of 5-alpha reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review. Aging Male 2019; 1-8.

  26. Shiota M, Kiyoshima K, Yokomizo A, et al. Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor. J Urol. 2017;197:308–13.

    Article  CAS  Google Scholar 

  27. Lombard AP, Mudryj M. The emerging role of the androgen receptor in bladder cancer. Endocr Relat Cancer. 2015;22:265–77.

    Article  Google Scholar 

  28. Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder cancer. Cancers (Basel). 2017;9:20–33. https://doi.org/10.3390/cancers9020020.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Keio University School of Medicine, Tokyo, Japan

    Ryohei Kufukihara MD, Koichiro Ogihara MD, PhD, Keisuke Shigeta MD, Yoshinori Yanai MD, Kimiharu Takamatsu MD, Ryuichi Mizuno MD, PhD & Mototsugu Oya MD, PhD

  2. Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan

    Eiji Kikuchi MD, PhD

  3. Department of Urology, Saiseikai Central Hospital, Tokyo, Japan

    Hiroki Ide MD, PhD

  4. Department of Urology, Saitama Medical University International Medical Center, Saitama, Japan

    Masafumi Oyama MD, PhD

  5. Department of Urology, Saitama Medical University Hospital, Saitama, Japan

    Hirotaka Asakura MD, PhD

Authors
  1. Ryohei Kufukihara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiji Kikuchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichiro Ogihara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keisuke Shigeta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinori Yanai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kimiharu Takamatsu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Ide MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masafumi Oyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirotaka Asakura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ryuichi Mizuno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mototsugu Oya MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Kikuchi MD, PhD.

Ethics declarations

Disclosure

No conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kufukihara, R., Kikuchi, E., Ogihara, K. et al. Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer. Ann Surg Oncol 28, 5349–5359 (2021). https://doi.org/10.1245/s10434-021-09750-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09750-0

Search

Navigation